Finally, recently promising results were shown for temelimab, a monoclonal immunoglobulin (Ig) G4, in the treatment for MS, targeting the HERV-W-Env, while its potential efficacy in type I diabetes mellitus has also been indicated [100,101]. Here, ERVW-1 is linked to myeloid sarcoma.